NYSE:OGNPharmaceuticals
A Look At Organon (OGN) Valuation After Positive VTAMA Phase 3 Post Hoc Analysis Results
Organon (OGN) is back in focus after presenting a post hoc pooled analysis of its Phase 3 ADORING 1 and 2 trials for VTAMA cream at the 2026 American Academy of Dermatology meeting.
See our latest analysis for Organon.
Despite the upbeat VTAMA data, Organon’s 1-day share price return of 4.87% and 30-day share price return of 7.77% sit within a much weaker pattern. The 90-day share price return of 25.03% and 1-year total shareholder return of 51.21% point to fading momentum overall.
If this...